Spinal metastasis subjected to photodynamic therapy: an update.

Jerjes, Waseem; Tan, HB; Hopper, Colin; Giannoudis, PV

doi:10.13172/2050-2303-1-1-256

Cited by 3 publications

(2 citation statements)

References 18 publications

(117 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preliminary results of an ongoing clinical trial with belomycin/Amphinex have shown good response in different human tumors, including advanced sarcomas [118], supporting further clinical investigation as a possible rescue treatment for relapsed patients. Targeting the insulin-like growth factor system is an attractive treatment option for cancers such as bone sarcomas, in which this pathway plays an important role for tumor development and growth [120].…”

Section: Bleomycin and Amphinexmentioning

confidence: 90%

Advances in emerging drugs for osteosarcoma

Hattinger

Fanelli

Tavanti

et al. 2015

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

OS is a heterogeneous tumor, with a great variability in treatment response between patients. It is therefore unlikely that a single therapeutic tool will be uniformly successful for all OS patients. This claims for the validation of new treatment approaches together with biologic/(pharmaco)genetic markers, which may select the most appropriate subgroup of patients for each treatment approach. Since some promising novel agents and treatment strategies are currently tested in Phase I/II/III clinical trials, we may hope that new therapies with superior efficacy and safety profiles will be identified in the next few years.

show abstract

Section: Bleomycin and Amphinexmentioning

confidence: 90%

Advances in emerging drugs for osteosarcoma

Hattinger

Fanelli

Tavanti

et al. 2015

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

show abstract

“…To further improve bleomycin efficacy, recently photochemical internalization techniques were used to enhance drug transport into tumor cells and showed promising activity in advanced sarcomas [5,67].…”

Section: Bleomycinmentioning

confidence: 99%

Pharmacogenomics of Second-Line Drugs Used for Treatment of Unresponsive or Relapsed Osteosarcoma Patients

Hattinger¹,

Vella²,

Tavanti³

et al. 2016

Pharmacogenomics

View full text Add to dashboard Cite

Second-line treatment of high-grade osteosarcoma (HGOS) patients is based on different approaches and chemotherapy protocols, which are not yet standardized. Although several drugs have been used in HGOS second-line protocols, none of them has provided fully satisfactory results and the role of rescue chemotherapy is not well defined yet. This article focuses on the drugs that have most frequently been used for second-line treatment of HGOS, highlighting the present knowledge on their mechanisms of action and resistance and on gene polymorphisms with possible impact on treatment sensitivity or toxicity. In the near future, validation of the so far identified candidate genetic biomarkers may constitute the basis for tailoring treatment by taking the patients' genetic background into account. Osteosarcoma is the most common tumor of bone, which can exibit different levels of malignancy [1,2]. High-grade osteo sarcoma (HGOS) is a very aggressive neoplasm that, in unselected populations, is responsible for death of approximately 40-50% of patients [2,3]. The subgroup of the so-called conventional HGOS includes patients with high-grade tumors located in the extremities, nonmetastatic at diagnosis and younger than 40 years [1]. In this subgroup of HGOS, prognosis is slightly better, reaching 60-65% when patients are treated with multiagent neoadjuvant chemotherapy [4][5][6].The major clinical problem limiting the cure rate of HGOS patients is relapse, which in most cases consists in development of lung metastasis within the first 24-36 months from diagnosis [7,8]. Treatment of relapsed HGOS is based on different approaches and second-line chemotherapy protocols which, however, are not standardized and can rescue no more than 20-25% of patients [4,5]. Methods of data searching & selectionA systematic literature search was performed using 'treatment' and 'osteosarcoma' as key words in PubMed [9]. We further restricted the selection to studies performed in humans. By using all the aforementioned different combinations and selections, the literature searches revealed a total of 13,976 results. The key terms 'polymorphism', 'toxicity', 'drug response', 'drug resistance', 'pharmaco genetic', 'pharmacogenomic', 'epigenetic', 'methylation' and 'clinical trial' were then used to refine the results of the previous search, in order to select the publications which were strictly related to each section of this review. Full-length articles and reviews in English were taken into consideration.Only drugs used in at least two different clinical trials with published results were included in this review and, consequently, we considered genes and gene poly morphisms with possible relevance for response and/or

show abstract